Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients

Rheumatology

Volumn 50, Issue 2, 2011, Pages 417-419

  Miettunen, Paivi M ^a   Narendran, Aru ^a   Jayanthan, Aarthi ^a   Behrens, Edward M ^b   Cron, Randy Q ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; ETOPOSIDE; HEMOGLOBIN; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT ONSET STILL DISEASE; CYTOPENIA; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; JUVENILE RHEUMATOID ARTHRITIS; LETTER; MACROPHAGE ACTIVATION SYNDROME; NEUTROPHIL COUNT; PANNICULITIS; PRIORITY JOURNAL; REMISSION; RHEUMATIC DISEASE; RHEUMATIC FEVER; SINGLE DRUG DOSE; SPLENOMEGALY; THROMBOCYTE COUNT; VASCULITIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTERLEUKIN-1; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MALE; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 78751681576     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq218     Document Type: Letter

References (10)

1. Chen HH, Kuo HC, Wang L et al. Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan. J Microbiol Immunol Infect 2007;40:265-71.
2. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
3. Henter JI, Samuelsson-Horne A, Arico M et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002;100:2367-73.
4. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
5. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-8.
6. Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006;33:2081-4.
7. Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol 2010;37:879-80.
8. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4:615-20.
9. Ravelli A, Magni-Manzoni S, Pistorio A et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604.
10. Henter JI, Horne A, Arico M et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48: 124-31.